Overview
Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome
Status:
Completed
Completed
Trial end date:
2005-09-01
2005-09-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This trial is conducted in Europe. The aim of this trial is to evaluate the effect of somatropin (Norditropin®) on final height in children with Noonan syndrome having being treated for up to 10 years with somatropin (Norditropin®) for the attainment of an optimal final height in the original trial S/GHD/004/NOO.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Novo Nordisk A/S
Criteria
Inclusion Criteria:- Participation in the original S/GHD/004/NOO trial or following the protocol for
S/GHD/004/NOO without being randomised in the trial